Correvio Pharma (CORV) Misses Q3 EPS by 6c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. DPZ
2. NVDA
3. BAC
4. UNH
5. ORCL
6. GS
7. AVAV
8. META
9. VSTM
10. DVLT

Go back to Correvio Pharma (CORV) Misses Q3 EPS by 6c, Revenues Miss

Correvio Reports Third Quarter 2019 Financial Results

November 14, 2019 7:00 AM EST

NASDAQ: CORV  TSX: CORV

FDA Accepts Brinavess New Drug Application

Advisory Committee Date Set for December 10, 2019

PDUFA Date Set for December 24, 2019

Management to Host Conference Call and Webcast Today, November 14, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific)

VANCOUVER, Nov. 14, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for its third quarter... More